Epigenetic modulation of the immune function
A potential target for tolerance

Beatriz Suárez-Álvarez,1 Aroa Baragaño Raneros,1 Francisco Ortega2,3 and Carlos López-Larrea1,3*

1Department of Immunology; Hospital Universitario Central de Asturias; Oviedo, Spain; 2Department of Nephrology; Hospital Universitario Central de Asturias; Oviedo, Spain; 3Fundación Renal Iñigo Alvarez de Toledo; Madrid, Spain

†Current affiliation: Cellular Biology in Renal Diseases Laboratory; Instituto de Investigación Sanitaria Fundación Jiménez Díaz; Universidad Autónoma Madrid; Madrid, Spain

Keywords: DNA methylation, histone modifications, rejection, tolerance

Great efforts in the field of solid organ transplantation are being devoted to identifying biomarkers that allow a transplanted patient’s immune status to be established. Recently, it has been well documented that epigenetic mechanisms like DNA methylation and histone modifications regulate the expression of immune system-related genes, modifying the development of the innate and adaptive immune responses. An in-depth knowledge of these epigenetic mechanisms could modulate the immune response after transplantation and to develop new therapeutic strategies. Epigenetic modifiers, such as histone deacetylase (HDAC) inhibitors have considerable potential as anti-inflammatory and immunosuppressive agents, but their effect on transplantation has not hitherto been known. Moreover, the detection of epigenetic marks in key immune genes could be useful as biomarkers of rejection and progression among transplanted patients. Here, we describe recent discoveries concerning the epigenetic regulation of the immune system, and how this knowledge could be translated to the field of transplantation.

Introduction

The immune response to an allograft is one of the biggest barriers to successful transplantation. The type and strength of response is determined by the cell type and cellular conditions under which it occurs. External (infections, chemical agents and drugs) and internal (cytokines and hormones) environmental stimuli can modify the epigenetic profile of a gene, directly influencing its expression and, ultimately, the cell type and immune response. Our knowledge of the epigenetic mechanisms involved in the development and differentiation of the immune system, and consequently that of related pathologies (autoimmune diseases and hematological disorders), has advanced considerably in recent years.1,2 Transplantation was the last component to be added to the list, showing that monitoring these epigenetic changes or modifying the immune response through epigenetic modifiers could help follow up transplanted patients and reduce the adverse effects of current immunosuppressive therapies.3-5

The epigenome connects the genome with the cellular environment and determines cellular identity and functionality. DNA methylation and histone post-translational modifications act in concert to establish an open or closed chromatin structure and ultimately define active or inactive gene transcription (Fig. 1A). In general, DNA hypermethylation is associated with repressive chromatin while histone marks are known to work in a synergistic way to activate or silence genes.6,7 These epigenetic modifications are established in specific residues by the action of several enzymes, including DNA methyltransferases (DNMTs), histone acetyltransferases (HATs), histone deacetylases (HDACs), histone methyltransferases (HMTs) and phosphatases, among others. Aberrant changes in these proteins or their targets enable gene expression to be modified and disrupt the cellular machinery contributing to alterations of the immune cell homeostasis. Thus, defining and modifying the “normal” epigenetic landscape of cells of the immune system could have important clinical consequences for the diagnosis and treatment of transplanted patients.

Against this background, several international projects such as the ENCODE project (Encyclopedia of DNA Elements, www.encodeproject.org/ENCODE) and the NIH Roadmap Epigenomics Program (www.roadmapepigenomics.org) have been undertaken to create a resource of epigenomic maps in a variety of primary human cells and tissues in order to determine how these epigenetic mechanisms contribute to disease.5,9 Additionally, the BLUEPRINT (www.blueprint-epigenome.eu) and DEEP (www.deutsches-epigenom-programm.de) consortia are focused on creating reference epigenomes of hematopoietic cells from healthy donors and from patients with malignant diseases (leukemias and autoimmune diseases) or cells and tissues from metabolic and inflammatory diseases, respectively.10 All these projects, now coordinated by the International Human Epigenome Consortium (IHEC; www.ihec-epigenomes.org),
Figure 1. Epigenetic regulation of the immune response in transplantation. (A) DNA methylation and histone modifications allow changes in chromatin structure that influence gene transcription. DNA methylation (black circles) and repressive histone marks (H3K27me3, H3K9me3, etc.) are associated with closed chromatin and gene repression while DNA demethylation (white circles) and active histone modifications (AcH3, AcH4, H3K4me3, H3K36me3, etc.) are correlated with an open chromatin structure, facilitating transcription factor binding and transcription. Enzymes such as histone acetyltransferases (HATs), histone deacetylases (HDACs), histone methyltransferases (HMTs), histone demethylases (HDMTs) and DNA methyltransferases (DNMTs), establish and maintain the balance between these modifications. (B) Changes in the chromatin structure of key genes in the immune responses that take place in organ transplantation can contribute to alloimmunity or tolerance. Epigenetic modifications (DNA methylation and histone modifications) regulate gene expression in different cell types in several ways: (1) the expression of pro-inflammatory (IL-1β, IL-6, IL-12) cytokines; (2) DNA demethylation and histone deacetylation increase the stable expression of the FoxP3 transcription factor, strengthening the suppressive function of Treg cells; (3) in CD4+ T cells, the differentiation of naive CD4+ T cells into helper T cells (Th1, Th2, Th17) and the plasticity among them is modulated; (4) the transcription of cytotoxic molecules (granzyme B and perforin) and activating receptors (NKG2D) is inhibited, and the expression of inhibitory KIR is enhanced in memory CD8+ T cells and NK cells, promoting allograft acceptance; (5) mature B cell differentiation into antibody-producing cells is controlled, decreasing allore cognition by donor-specific antibodies and preventing graft rejection. DNA methylation and demethylation are represented by black and white lollipops, respectively; histone modifications are shown as circles: green, H3K4me3; red, H3K27me3; purple, H3K9me3; blue, acetylation of H3 or H4.
Dendritic cells (DCs) are essential mediators of the innate and adaptive immune response, and can induce immunity or tolerance.\textsuperscript{11,12} In the initial stages after transplantation, DCs orchestrate inflammation subsequent to ischemia-reperfusion injury or indirectly lead to the activation of effector T lymphocytes and natural killer cells. However, in the absence of inflammatory signals and because of their phenotypic plasticity, DCs may also induce tolerance. Epigenetic mechanisms are involved during the differentiation of human monocyte-derived DCs (moDCs) and the critical “decision” to become activated or tolerogenic cells. Exposure to appropriate stimuli promotes differentiation of monocytes into DCs, leading to CD14 downregulation and increased expression of DC-SIGN (CD209), an essential molecule for trafficking DC and establishing DC-T cell contact. This process is regulated by the acquisition of an active histone mark (H3K9Ac) in CD209 gene along with the loss of repressive marks (H3K9me3, H4K20me3) and DNA methylation.\textsuperscript{13} Additionally, the balance between the active H3K4me3 and repressive H3K27me3 histone marks in specific genes is associated with changes in gene expression, allowing the differentiation and function of activated or tolerized moDCs.\textsuperscript{14}

Cell therapy with tolerogenic DCs (TolDCs) is currently an attractive approach to minimizing the use of immunosuppressive drugs in transplantation.\textsuperscript{15} Administration of TolDCs in several animal models of transplantation has shown improved graft survival and function although the current goal is to transfer this knowledge to humans. Epigenetic modifiers, such as HDAC inhibitors, can affect DC functions, revealing broader implications for immunotherapeutic strategies.\textsuperscript{16} Treatment of DCs with Valproate and Butyrate reduce the expression of co-stimulatory molecules (CD40, CD80 and CD86) and secretion of pro-inflammatory cytokines (TNFα, IL-1β, IL-6 and IL12), inhibiting the activation of Th1 and Th17 responses and the expression of granzyme B in stimulated CD8+ T cells.\textsuperscript{17,18} Disruption of HDAC11 in antigen presenting cells (APCs) upregulates the expression of the IL10 gene and impairs the antigen-specific T cell responses, making this a promising target for inducing immune tolerance.\textsuperscript{19}

**Plasticity of the CD4 T Cell Subsets:**

**Effector and Regulatory Balance**

After antigen recognition, naive T cells differentiate into effector T “helper” cells (Th1, Th2 and Th17) or regulatory T (Treg) cells with a suppressive function (Fig. 2).\textsuperscript{20} The appropriate balance between effector and regulatory T cell subsets determines the rejection or tolerance of the transplanted graft. Differentiation of naive CD4+ T cells toward one or other lineage is determined by the strength of the encounter with foreign antigens presented by the APCs and the presence of cytokines in the microenvironment where they occur. These signals enable changes in the expression of transcription factors that are correlated with epigenetic changes at specific loci, thereby establishing stable differentiation lineages.\textsuperscript{21,22}

The first studies in humans showed that Th1 and Th2 cells are true lineages regulated by epigenetic modifications in IFNG, IL4 and IL13 genes allowing differentiation into a lineage with the extinction of the opposite fate. The INFG promoter is hypermethylated in human naive T cells and is only demethylated during the differentiation to Th1 cells.\textsuperscript{23} By contrast, IL4 promoter is highly methylated in naive and Th1 cells, and only partial demethylation, specific to Th2 cells, is observed in intron 2 of IL4 and the IL13 promoter region.\textsuperscript{24} Moreover, epigenetic histone marks are also essential for the Th1/Th2 cell fate decisions. Key transcription factors for the Th1 (STAT4 and T-bet) or Th2 (STAT6 and GATA-3) lineage choice are critical to the establishment of histone marks across the IFNG locus. This gene displays acetylation of H4 (AcH4) and H3K4-trimethylation marks in Th1 cells in combination with H3K27 di- and tri-methylation in Th2 cells.\textsuperscript{25} The histone methylase SUV39H1, which is involved in the trimethylation of H3K9 (H3K9me3), has recently been implicated in the silencing of the Th1 locus and the subsequent promotion of stability of Th2 cells.\textsuperscript{26}

The discovery of two new, more flexible lineages of CD4+ T cells, Th17 and induced regulatory T (iTreg) cells, has greatly complicated the landscape of CD4+ T cell differentiation.\textsuperscript{27,28}
Th17 cells are defined by the specific expression of the RORγt (also known as RORC) transcription factor and IL17 production and potentially contribute to allograft rejection. By contrast, Treg cells are fundamental for maintaining immunological tolerance and immune homeostasis. In vivo-isolated human Th17 cells are characterized by DNA demethylation in IL17A and RORC loci correlated with specific expression in these cells, and the presence of bivalent H3K4me3/H3K27me3 domains at the TBX1 (T-box 21) promoter, suggesting that this gene is poised to be rapidly expressed under particular conditions. Treg cells can originate as a stable subset from the thymus or be induced at the periphery by exposure to TGF-β, in both cases being characterized by the continuous expression of the transcription factor FoxP3. DNA demethylation in a conserved noncoding region of the FOXP3 gene, known as TSDR (Treg cell-specific demethylation region), and hyperacetylation of histones are responsible for maintaining the stable expression of FOXP3 and the correct function of Treg cells. As mentioned above, epigenetic mechanisms are intricately coupled to the differentiation of CD4+ T cells, facilitating the heritability and lineage stability of these subsets. However, simultaneously, these mechanisms may be altered at any point, favoring
plasticity and producing a more effective immune response.\textsuperscript{37-40} This elevated plasticity among CD4+ T cell types has revealed the immunological circumstances of rejection to be more complicated than previously thought. During chronic inflammation, Th17 cells can express IFN-γ and IL17 concomitantly, giving rise to an intermediate Th1/Th17 phenotype. These cells have an epigenetic profile similar to that of Th17 cells, but retain the demethylated IFNG gene and lose the repressive H3K27me3 mark of the bivalent domain in TBX21 gene, inducing IFN-γ expression and contributing to the damage of the transplanted graft.\textsuperscript{32} Moreover, Th17 cells have the capacity to differentiate into FoxP3+ cells with a suppressive function after continuous in vitro TCR stimulation by partial demethylation of the FOXP3 gene, although this matter is still controversial.\textsuperscript{41}

A challenge for the treatment of allograft rejection and induction of tolerance is to focus on cell therapy with Treg cells.\textsuperscript{32} A major inconvenience, however, is the loss of FoxP3 expression and reprogramming into effector T cells secreting IL-17 and IFN-γ in a pro-inflammatory microenvironment. Memory Tregs can become IL-17+ cells through DNA demethylation of the RORC locus.\textsuperscript{43} However, although Treg cells can lose FoxP3 expression, they maintain the demethylated status of TSDR and retain the ability to reactivate FoxP3 expression and the suppressive function upon activation.\textsuperscript{44} Thus, the DNA methylation status of TSDR could be used for specifically identifying genuine suppressor Treg cells during clinical follow-up of transplanted patients.\textsuperscript{45}

Additionally, the use of epigenetic treatments could be exploited to generate functionally stable Treg cells. Inhibition of DNA methylation by DNMT inhibitors (5AzaC or DAC), in the presence or absence of TGF-β, promotes stable induction of FoxP3 expression). The inhibition of the histone deacetylases HDAC6, HDAC9 or Sirtuin-1 (Sirt1) is known to enhance the suppressive function of Treg cells additively.\textsuperscript{46,47} Targeting these enzymes with specific pharmacological inhibitors is an exciting therapeutic option for increasing Treg function in transplanted patients.

Establishing T-Cell Memory and NK-Cell Identity

The immunological history of a transplant recipient influences the graft outcome. Transplanted patients with a higher frequency of donor-specific memory T cells have a higher risk of alloreactive memory T cell-mediated rejection and of being a barrier to tolerance.\textsuperscript{28} During memory T cell formation, epigenetic changes in transcription factors (T-bet and comesodermin), cytokines (IL-2 and IFN-γ) and other molecules (CD70, CD40L, ITGAL, PRF and CCR6) are essential for controlling the transcriptional profiles and function of these cells.\textsuperscript{49} For example, in memory CD4+ T cells, demethylation of the CCR6 gene enables the stable expression of this chemokine, facilitating migration of these cells toward the renal proximal tubular epithelial cells, where they carry out their function.\textsuperscript{50} In memory CD8+ T cells, hyperacetylation of histone 3 lysine 9 (H3K9Ac) in effector molecules (Eomes, PRF and GRZ) permits a stronger and quicker cytotoxic response to subsequent antigen re-encounters.\textsuperscript{51} It is thought that these chromatin changes are established during the effector phase and maintained in the memory phase in addition to new modifications in gene loci that are differentially expressed in memory T cells. Genome-wide analysis of histone methylation (H3K4me3 and H3K427/me3) in CD8+ memory T cells identifies four epigenetic states (active, poised, bivalent and repressed), reflecting the function of various genes in these cells.\textsuperscript{52}

During chronic viral infections (CMV, HCV and HIV), demethylation in the PDCD1 locus (encodes PD-1) in exhausted memory CD8+ T cells enables its expression, damaging the resolution of the infection.\textsuperscript{53,54} Understanding how the epigenetic modifications are established in memory T cells will allow us to develop strategies for targeting these cells and avoiding unwanted immune responses to transplanted grafts, and for improving long-term protection against infections.

NK cells play a fundamental role in the alloimmune and anti-infectious responses, since they are associated with inflammatory and regulatory functions.\textsuperscript{39} Depending on the early activation of NK cells after SOT and the type of NK cell receptors expressed, these cells can promote rejection or tolerance. This is particularly relevant in the early stages of transplantation when it is essential to avoid elimination of the graft by NK cells while maintaining its anti-viral immune response function that commonly develops in transplanted patients. Several studies have demonstrated that epigenetic modifications modulate the cytolytic activity of NK cells regulating the expression of some NK cell receptors (KIR, NCRs and NKG2D) and cytotoxic molecules (GRZ and PRF).\textsuperscript{55-58} Treatments with demethylating agents (5azaC and DAC) increase the expression of inhibitory KIRs, while HDAC inhibitors decrease the expression of the activating Nkp46 and Nkp30 receptors. Our group has recently demonstrated that the NKG2D-activating receptor is regulated by histone acetylation (H3K9Ac) and that inhibition of histone acetyltransferase (HAT) activity by curcumin not only downregulates its expression at the cell surface but also leads to a marked reduction in the lytic capacity of NK cells.\textsuperscript{29} Further studies are needed to clarify the epigenetic mechanisms involved in regulating all the inhibitory and activator receptors and their contribution to NK cell function.

Targeting of Plasma Cell Differentiation

There is clear evidence of the role played by B cells, plasma cells and their secreted antibodies in the acute cellular rejection and in acute and chronic antibody-mediated rejection.\textsuperscript{60} Studies using “omics” assays showed a functional balance between different B-cell subsets, some aimed at inducing organ injury (plasmatic B cells) and others involved in tolerance (transitional and regulatory B cells).\textsuperscript{61}

Differentiation of hematopoietic stem cells into antibody-producing B cells requires a complex epigenetic regulatory mechanism that produces changes in chromatin structure throughout B cell development.\textsuperscript{52-64} Altered DNA demethylation patterns within gene bodies outside of CpG islands are essential for the correct differentiation and function of B cells.\textsuperscript{65} At early stages, demethylation of transcription factors (Pax5 and PU1) and their
Therefore, it is necessary to develop non-invasive biomarkers that allow the early detection of patients who have developed immunological unresponsiveness (total or partial) toward their graft, either spontaneously or through active tolerance induction. In recent years, European and other international networks (IOT, ITN and RISET) have integrated various “omics” technologies (genomics, proteomics and transcriptomics) and platforms to identify biomarkers reflecting the immune status of transplanted patients.

The use of epigenetic biomarkers, mainly based on DNA methylation, is well established for the diagnosis and prognosis of tumors and has begun to be understood in other pathologies such as autoimmune diseases. The identification of DNA methylation and histone modification marks in immune function-related genes could encourage the development of new epigenetic-based post-transplant biomarkers that have direct applications in clinical practice. Recently, our group has reported that methylation changes in blood from patients with hematopoietic cell transplant are linked to physiological changes during transplant evolution. Identification of the DNA methylation level for IFNG, FASL and IL-10 genes could be used as potential biomarkers for the development of graft-versus-host diseases. Moreover, demethylation of FoxP3 gene in biopsies from kidney transplant patients with subclinical rejection has been associated with a better long-term allograft outcome. Novel epigenetic biomarkers targeting genes [CD79A (mb1), CD19 and IRF4] is essential to establish a functional expression pattern in B cells and to initiate immunoglobulin V(D)J recombination. In later stages, naïve B cells migrate to germinal centers, where they are activated by antigen encounter and become antigen-experienced plasma cells producing antibodies or memory B cells. The activation-induced by cytidine deaminase (AID) enzyme, which plays a critical role in the processes of somatic hypermutation and class switch recombination, resulting in diversification and high-affinity antibody production, is involved in the active DNA demethylation process. Moreover, the transcriptional repressor Blimp-1, which suppresses the mature B-cell gene expression favoring formation of antibody-secreting cells, functions by interacting with the LSD1 histone lysine demethylase. Further studies of these mechanisms are needed to determine whether targeting these enzymes could help attenuate antibody production.

**Epigenetic Biomarkers and New Therapeutic Targets**

Identification of tolerant patients is the cornerstone of transplantation medicine. There is currently an absence of adequate robust biomarkers, which are necessary for monitoring the immune response. These are needed to reduce the level of immunosuppressive therapy and to improve long-term transplant outcomes definitively. Therefore, it is necessary to develop non-invasive biomarkers that allow the early detection of patients who have developed immunological unresponsiveness (total or partial) toward their graft, either spontaneously or through active tolerance induction. In recent years, European and other international networks (IOT, ITN and RISET) have integrated various “omics” technologies (genomics, proteomics and transcriptomics) and platforms to identify biomarkers reflecting the immune status of transplanted patients.

The use of epigenetic biomarkers, mainly based on DNA methylation, is well established for the diagnosis and prognosis of tumors and has begun to be understood in other pathologies such as autoimmune diseases. The identification of DNA methylation and histone modification marks in immune function-related genes could encourage the development of new epigenetic-based post-transplant biomarkers that have direct applications in clinical practice. Recently, our group has reported that methylation changes in blood from patients with hematopoietic cell transplant are linked to physiological changes during transplant evolution. Identification of the DNA methylation level for IFNG, FASL and IL-10 genes could be used as potential biomarkers for the development of graft-versus-host diseases. Moreover, demethylation of FoxP3 gene in biopsies from kidney transplant patients with subclinical rejection has been associated with a better long-term allograft outcome.

### Table 1. Epigenetic modifications as potential biomarkers of tolerance after solid organ transplantation

| Gene      | Cell type | Gene function | Epigenetic modification                                      |
|-----------|-----------|---------------|--------------------------------------------------------------|
| IFNG      | CD4 (Th1), CD8, NK | Interleukin | DNA methylation, histone acetylation and methylation |
| TBX21 (T-bet) | CD4 (Th1) | Transcription factor | DNA methylation, bivalent domains |
| IL4       | CD4 (Th2) | Interleukin | DNA methylation, histone methylation |
| IL13      | CD4 (Th2) | Interleukin | DNA methylation |
| GATA3     | CD4 (Th2) | Transcription factor | Bivalent domains |
| IL17      | CD4 (Th17) | Interleukin | DNA methylation |
| RORC (ROR-γt) | CD4 (Th17) | Transcription factor | DNA methylation, bivalent domains |
| FoxP3     | CD4 (Treg) | Transcription factor | DNA methylation, histone acetylation |
| CCR6      | CD4       | Chemokine receptor | DNA methylation |
| CD40L     | CD4       | Costimulatory molecule | DNA methylation |
| IL2       | CD4, CD8  | Interleukin | DNA Methyltyion, histone acetylation |
| PDCD1 (PDI) | CD8       | Costimulatory molecule | DNA methylation |
| EOMES     | CD8, NK   | Transcription factor | Histone acetylation |
| GRZB      | CD8, NK   | Cytotoxic molecule | Histone acetylation |
| PRF1      | CD8, NK   | Cytotoxic molecule | DNA methylation, histone acetylation |
| KLRC1 (NKG2D) | NK, CD8 | Activating receptor | DNA methylation, histone acetylation |
| KIRs      | NK        | Activating and inhibitory receptor | DNA methylation and histone methylation |
| FASL      | NK        | Apoptosis | DNA methylation, histone acetylation |
| CD19      | B         | Surface receptor | DNA methylation |
| PRDM1 (BLIMP1) | B | Transcriptional repressor | Histone methylation |
| IL10      | Mo, DC, B, Treg | Interleukin | DNA methylation |
| IL1B      | Mo, MΦ   | Interleukin | DNA methylation |
| CD209     | DC, MΦ   | Surface receptor | Histone acetylation and methylation |

Bivalent domains, H3K4me3/H3K27me3; Mo, monocyte; MΦ, macrophage; DC, dendritic cells; NK, natural killer cells
will help to establish an “immunological fingerprint” of rejection risk or tolerance during follow-up of transplanted patients.

From a clinical perspective, one of the most important characteristics of epigenetic modifications is that they can be reverted using enzymatic treatments (such as DNMT and HDAC inhibitors). Some of these epigenetic drugs (5-Azacytidine, Decitabine, Vorinostat and Romidepsin) have been approved by the US Food and Drug administration (FDA) for the treatment of hematologic diseases and many phase II and III clinical trials are under development. Although it has not been extensively studied, preliminary data suggest that treatment with epigenetic modifiers in combination with current immunosuppressant therapies prolongs allograft survival in animal models of cardiac and renal transplant.

In humans, curcumin (a HAT inhibitor) in combination with cyclosporine A can suppress the induction of Th1 diseases and many phase II and III clinical trials are under FDA administration (FDA) for the treatment of hematologic diseases. Some of these epigenetic drugs (5-Azacytidine, Decitabine, Vorinostat and Romidepsin) have been approved by the US Food and Drug administration (FDA) for the treatment of hematologic diseases and many phase II and III clinical trials are under development. Although it has not been extensively studied, preliminary data suggest that treatment with epigenetic modifiers in combination with current immunosuppressant therapies prolongs allograft survival in animal models of cardiac and renal transplant. In humans, curcumin (a HAT inhibitor) in combination with cyclosporine A can suppress the induction of Th1 cytokines in ex vivo peripheral blood lymphocytes from kidney transplant patients.

Current approaches for clinical use are based on the in vitro generation or ex-vivo expansion of regulatory immune cells, with the aims of creating a suppressive environment and improving long-term allograft survival or inducing transplantation tolerance. As we previously reported, epigenetic drugs have the ability to modify the expression of key genes during the generation of diverse types of regulatory cell (Fig. 2). Chromatin modifications are critical for the differentiation and maintenance of the suppressive functions of Treg cells, regulating the balance between effector and regulatory T cells, differentiating tolerogenic dendritic cells, or during the polarization toward regulatory macrophages, suggesting the potential utility of epigenetic treatments for producing immunoregulatory cells. Moreover, in recent years, cell therapies with mesenchymal stem cells (MSCs) have come to be recognized as an attractive strategy for tolerance induction in organ transplantation. The first clinical trials are underway. MSCs have immunomodulatory properties, damping the effector T-cell response and promoting the increase of regulatory T cells. However, during long-term cultures for therapies, these properties and the self-renewing capacity can be lost by chromatin alterations via epigenetic mechanisms. HDAC inhibitors are believed to maintain the biological characteristics of MSCs, thereby improving their usefulness in therapy.

One of the main inconveniences of the use of epigenetic treatments is that they are unspecific and may induce chromosomal instability that predisposes to cancer and makes it difficult to use for treating other pathologies. New therapeutic strategies aim to selectively target proteins that recognize modified histones, such as BET (bromodomain and extra terminal domain) family proteins, or alter DNA methylation in a specific way through artificial transcription factors or the thymine DNA glycosylase (TGD) enzyme. These new epigenetic approaches will allow the stable and heritable manipulation of the gene expression of target genes with significant functional relevance in immune system diseases and related conditions.

Concluding Remarks

Changes in chromatin structure arising from DNA methylation and histone modifications are involved in critical immune function pathways, such as generating monocyte-derived DC, differentiation and plasticity of “helper” CD4+ T cells and regulatory T cells, establishing a memory phenotype, and producing antibodies by plasma cells. Our growing knowledge of the epigenetic mechanisms involved in regulating the immune response will give us a more thorough understanding of the immunological processes involved in rejection and allograft tolerance. Therefore, we may be confident that in the coming years the identification of epigenetic alterations that occur during immune system deregulation after transplantation will lead to the development of new biomarkers. The advantage of these is that it will be possible to use non-invasive and stable DNA samples, combined with rapid, specific and quantitative methods such as pyrosequencing. These biomarkers are essential for identifying not only tolerant patients whose immunosuppressive therapy could be minimized or withdrawn, but also the early occurrence of graft rejection.

Additional studies will determine whether epigenetic treatments may one day become a valid therapeutic strategy for modulating the balance between immunity and tolerance. The potential usefulness of these epigenetic modifiers in combination with the immunosuppressant drugs currently used in clinical practice and their role in the ex vivo differentiation and maintenance of immunoregulatory cells needs to be established.

In conclusion, epigenomics is a growing area of transplant immunology research that could not only inspire new ways of immunologically monitoring transplanted patients but also lead to the development of new cell-based immunosuppressive strategies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

This work was supported by Spanish grants from Fondo de Investigaciones Sanitaria-Fondos FEDER European Union (FIS PI08/0566 and PI12/02587) and the Red de Investigación Renal (REDinREN RD12/0021) from the Institute Carlos III.

References

1. Rodriguez-Cortez VC, Hernando H, de la Rica L, Vento R, Ballestar E. Epigenomic deregulation in the immune system. Epigenomics 2011; 3:697-713; PMID:22126290; http://dx.doi.org/10.2217/epi.11.99
2. Suarez-Alvarez B, Rodriguez RM, Fraga MF, Lopez-Larraza C. DNA methylation: a promising landscape for immune system-related diseases. Trends Genet 2012; 28:506-14; PMID:22824525; http://dx.doi.org/10.1016/j.tig.2012.06.005
3. Schildberg FA, Hagmann CA, Bohnert V, Tolba RH. Improved transplantation outcome by epigenetic changes. Transpl Immunol 2010; 23:104-10; PMID:20471480; http://dx.doi.org/10.1016/j.trim.2010.05.001
4. McCaughan JA, McKnight AJ, Courtenay AE, Maxwell AP. Epigenetics: time to translate into transplantation. Transplantation 2012; 94:1-7; PMID:22437848; http://dx.doi.org/10.1097/TP.0b013e3182d4b9d
5. Rodríguez RM, Suarez-Alvarez B, Salvanés R, Muro M, Martínez-Camblor P, Colado E, et al. DNA methylation dynamics in blood after hematopoietic cell transplantation. PLoS One 2013; 8:e56931; PMID:23451113; http://dx.doi.org/10.1371/journal.pone.0056931
6. Kilis M, Esterler M. DNA methylation and cancer. Adv Genet 2010; 70:27-56; PMID:20920744; http://dx.doi.org/10.1016/B978-0-12-380866-0.00022-2
7. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011; 21:381-95; PMID:21324607; http://dx.doi.org/10.1038/cr.2011.22
8. Dunham I, Kundaje A, Alderlietoene TF, et al. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489:57-74; PMID:22955616; http://dx.doi.org/10.1038/nature11247
9. Kadisch KA, Jepson BH, Roadmap Epigenomics Program data resource. Epigenomics 2012; 4:337-24; PMID:22690667; http://dx.doi.org/10.2174/epi.12.18
10. Adams D, Almaci L, Antonarakis SE, et al. Epigenotype switching at the CD14 and CD209 genes during differentiation of human monocytes to dendritic cells. Epigenetics 2011; 6:45-51; PMID:20818162; http://dx.doi.org/10.4161/epi.6.1.13534
11. Moreau A, Varey E, Bouchet-Delbos L, Cuturi MC. Cell lineage commitment and functional plasticity of T regulatory cells. Immunity 2012; 36:267-76; PMID:22613285; http://dx.doi.org/10.1016/j.immuni.2012.06.005
12. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:17897860; http://dx.doi.org/10.1038/nature06175
13. Bullwinkel J, Lüdemann A, Debarry J, Singh PB. Epigenetic regulation of human monocyte-derived dendritic cells. Front Immunol 2012; 3:48-59; PMID:23096487; http://dx.doi.org/10.3389/fimmu.2012.00041
14. Aslam D, Almugni M, Morimoto K, Iwasaki A, et al. Dendritic cell differentiation and immunogenicity. Clin Dev Immunol 2012; 19:283-91; PMID:22728031; http://dx.doi.org/10.1155/2012/913476
15. Nencioni A, Beck J, Werth D, Grünebach F, Patrone F, Frikeche J, Peric Z, Brissot E, Grégoire M, Gaugler J, et al. Epigenetic silencing pathway controlling T cell self-tolerance maintenance. Nature 2012; 487:249-53; PMID:22763435; http://dx.doi.org/10.1038/nature11713
16. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood 2013; 121:2402-14; PMID:23235825; http://dx.doi.org/10.1182/blood-2012-09-378653
17. Okhäuser N, Hamaguchi M, Morigaki H, Sugimura K, Tanaka A, Ito Y, et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunology 2012; 137:795-80; PMID:22132060; http://dx.doi.org/10.1111/j.1365-2567.2012.03679.x
18. Wang B, Morinobu A, Horiuchi M, Liu J, Kumagai S. Butyrate inhibits functional differentiation of human monocyte-derived dendritic cells. Cell Immunol 2007; 248; PMID:17546033; http://dx.doi.org/10.1016/j.immuni.2008.12.009
19. Merad M, Collin M, Bromberg J. Dendritic cell homeostasis and trafficking in transplantation. Trends Immunol 2007; 28:353-9; PMID:17618832; http://dx.doi.org/10.1016/j.it.2007.06.003
20. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+T cell differentiation and immunogenicity. Immunol Res 2012; 52:32-42; PMID:21756035; http://dx.doi.org/10.1080/16006143.2012.684145
Amaravadi L, Klemsz MJ. DNA methylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells. Epigenetics 2013; 8:53; PMID:23752476; http://dx.doi.org/10.4161/epi.25353.

Li G, Yu M, Weyand CM, Goronzy JJ. Epigenetic modification of proteins in committed B cells. EMBO J 2009; 28:3414-25; PMID:19706685; http://dx.doi.org/10.1038/nri1119.

Walter K, Boediger C, Tagoh H. Stem cell-specific epigenetic priming and B cell-specific transcriptional activation at the mouse Cd19 locus. Blood 2008; 112:1673-82; PMID:18552207; http://dx.doi.org/10.1182/blood-2008-02-142786.

Marbañón LS, MOT. DNA methylation and histone H3K4 acetylation mediate B cell reactivity while decitabine augments NK cell cytolytic activity. FEBS Lett 2007; 581:1317-22; PMID:17349632; http://dx.doi.org/10.1016/j.fle.2007.02.045.

Schmiedel BJ, Arellán G, Vrevenbach E, Krausch M, Schmidt SM, Sahli HR. Acetylation impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 2011; 128:2911-22; PMID:20906460; http://dx.doi.org/10.1002/cncr.25613.

Lu Y, Mo W, Woydan CM, Goronzy JJ. Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells. Blood 2009; 114:3422-30; PMID:19628706; http://dx.doi.org/10.1182/blood-2009-01-200170.

Fernández-Sánchez A, Baragán Ramero A, Carvalho Palau B, Sanz AB, Zurita A, Ortega F, et al. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKGD2 gene in human CD8+ T and NK cells. Epigenetics 2013; 8:66-76; PMID:23225319; http://dx.doi.org/10.4161/epi.25115.

Zarkhin V, Sarwal MM. The coin toss of B cells in rejection and tolerance: danger versus defense. Semin Immunol 2012; 24:86-91; PMID:22055649; http://dx.doi.org/10.1016/j.seminimunol.2011.09.003.

Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Reynolds AE, et al. Activation-induced cytidine deaminase deficiency is associated with renal transplant tolerance in humans. Nat Rev Nephrol 2010; 6:614-28; PMID:20361837; http://dx.doi.org/10.1038/nrneph.2010.110.

Naessens M, Sarwal MM. Molecular diagnostics in transplantation. Nat Rev Nephrol 2010; 6:451-68; PMID:20756923; http://dx.doi.org/10.1038/nrneph.2010.113.

Viklicky O, Krystufkova E, Brabcova I, Sekerkova A, Viklicky O, Krystufkova E, Brabcova I, Sekerkova A, et al. Histone deacetylase inhibitors suppress natural killer cell reactivity while decitabine augments NK cell cytolytic activity. FEBS Lett 2007; 581:1317-22; PMID:17349632; http://dx.doi.org/10.1016/j.fle.2007.02.045.

Karazia J, Hong S, Vanselow A, Kloss CM, Yang P, et al. Induction of histone deacetylase inhibitor expression in Blimp-1-mediated gene repression during plasma cell differentiation. Mol Cell Biol 2009; 29:1421-31; PMID:19124609; http://dx.doi.org/10.1128/MCB.01158-08.

Rödder S, Vitalone M, Khatri P, Sarwal MM, Roedder S, Vitalone M, Khatri P, Sarwal MM, et al. The aging of human umbilical cord mesenchymal stem cells. [Epup ahead of print]. J Cell Biochem 2013; 124:2566-76; http://dx.doi.org/10.1002/jcb.24569.

Dalen SR, Bellacosa A. DNA methylation by TDG. Epigenomics 2012; 4:241-7; PMID:22354705; http://dx.doi.org/10.1007/s10438-012-0501-6.

Dodds EW, Chen T, Qi H, Deng C, Ye T, et al. Role of histone demethylase LSD1 in Blimp-1-mediated gene repression during plasma cell differentiation. Mol Cell Biol 2009; 29:1421-31; PMID:19124609; http://dx.doi.org/10.1128/MCB.01158-08.

Naessens M, Sarwal MM. Molecular diagnostics in transplantation. Nat Rev Nephrol 2010; 6:451-68; PMID:20756923; http://dx.doi.org/10.1038/nrneph.2010.113.

Viklicky O, Krystufkova E, Brabcova I, Sekerkova A, Viklicky O, Krystufkova E, Brabcova I, Sekerkova A, et al. Histone deacetylase inhibitors suppress natural killer cell reactivity while decitabine augments NK cell cytolytic activity. FEBS Lett 2007; 581:1317-22; PMID:17349632; http://dx.doi.org/10.1016/j.fle.2007.02.045.

Reynolds AE, et al. Activation-induced cytidine deaminase deficiency is associated with renal transplant tolerance in humans. Nat Rev Nephrol 2010; 6:614-28; PMID:20361837; http://dx.doi.org/10.1038/nrneph.2010.110.

Naessens M, Sarwal MM. Molecular diagnostics in transplantation. Nat Rev Nephrol 2010; 6:451-68; PMID:20756923; http://dx.doi.org/10.1038/nrneph.2010.113.

Viklicky O, Krystufkova E, Brabcova I, Sekerkova A, Viklicky O, Krystufkova E, Brabcova I, Sekerkova A, et al. Histone deacetylase inhibitors suppress natural killer cell reactivity while decitabine augments NK cell cytolytic activity. FEBS Lett 2007; 581:1317-22; PMID:17349632; http://dx.doi.org/10.1016/j.fle.2007.02.045.

Reynolds AE, et al. Activation-induced cytidine deaminase deficiency is associated with renal transplant tolerance in humans. Nat Rev Nephrol 2010; 6:614-28; PMID:20361837; http://dx.doi.org/10.1038/nrneph.2010.110.